|
1
|
Smith TJ, Khatcheressian J, Lyman GH, Ozer
H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J,
Cross SJ, et al: 2006 update of recommendations for the use of
white blood cell growth factors: An evidence-based clinical
practice guideline. J Clin Oncol. 24:3187–3205. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aapro MS, Bohlius J, Cameron DA, Dal Lago
L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC,
Walewski J, et al: 2010 update of EORTC guidelines for the use of
granulocyte-colony stimulating factor to reduce the incidence of
chemotherapy-induced febrile neutropenia in adult patients with
lymphoproliferative disorders and solid tumours. Eur J Cancer.
47:8–32. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kosaka Y, Rai Y, Masuda N, Takano T, Saeki
T, Nakamura S, Shimazaki R, Ito Y, Tokuda Y and Tamura K: Phase III
placebo-controlled, double-blind, randomized trial of pegfilgrastim
to reduce the risk of febrile neutropenia in breast cancer patients
receiving docetaxel/cyclophosphamide chemotherapy. Support Care
Cancer. 23:1137–1143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Okamoto H, Watanabe K, Kunikane H,
Yokoyama A, Kudoh S, Asakawa T, Shibata T, Kunitoh H, Tamura T and
Saijo N: Randomised phase III trial of carboplatin plus etoposide
vs split doses of cisplatin plus etoposide in elderly or poor-risk
patients with extensive disease small-cell lung cancer: JCOG 9702.
Br J Cancer. 97:162–169. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yamamoto N, Sekine I, Nakagawa K, Takada
M, Fukuoka M, Tanigawara Y and Saijo N: A pharmacokinetic and dose
escalation study of pegfilgrastim (KRN125) in lung cancer patients
with chemotherapy-induced neutropenia. Jpn J Clin Oncol.
39:425–430. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee KH, Kim JY, Lee MH, Han HS, Lim JH,
Park KU, Park IH, Cho EK, Yoon SY, Kim JH, et al: A randomized,
multicenter, phase II/III study to determine the optimal dose and
to evaluate the efficacy and safety of pegteograstim (GCPGC) on
chemotherapy-induced neutropenia compared to pegfilgrastim in
breast cancer patients: KCSG PC10-09. Support Care Cancer.
24:1709–1717. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Masuda N, Tokuda Y, Nakamura S, Shimazaki
R, Ito Y and Tamura K: Dose response of pegfilgrastim in Japanese
breast cancer patients receiving six cycles of docetaxel,
doxorubicin, and cyclophosphamide therapy: A randomized controlled
trial. Support Care Cancer. 23:2891–2898. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang BB, Morrow PK, Wu X, Moxness M and
Padhi D: Comparison of pharmacokinetics and safety of pegfilgrastim
administered by two delivery methods: On-body injector and manual
injection with a prefilled syringe. Cancer Chemother Pharmacol.
75:1199–1206. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Matthews JH: Pulmonary toxicity of ABVD
chemotherapy and G-CSF in Hodgkin's disease: Possible synergy.
Lancet. 342:9881993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yokose N, Ogata K, Tamura H, An E,
Nakamura K, Kamikubo K, Kudoh S, Dan K and Nomura T: Pulmonary
toxicity after granulocyte colony-stimulating factor-combined
chemotherapy for non-Hodgkin's lymphoma. Br J Cancer. 77:2286–2290.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ruiz-Argüelles GJ, Arizpe-Bravo D,
Sánchez-Sosa S, Rojas-Ortega S, Moreno-Ford V and Ruiz-Argüelles A:
Fatal G-CSF-induced pulmonary toxicity. Am J Hematol. 60:82–83.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Adachi K, Suzuki M, Sugimoto T, Yorozu K,
Takai H, Uetsuka K, Nakayama H and Doi K: Effects of granulocyte
colony-stimulating factor (G-CSF) on bleomycin-induced lung injury
of varying severity. Toxicol Pathol. 31:665–673. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kudoh S, Kato H, Nishiwaki Y, Fukuoka M,
Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M, et
al: Interstitial lung disease in Japanese patients with lung
cancer: A cohort and nested case-control study. Am J Respir Crit
Care Med. 177:1348–1357. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Niitsu N, Iki S, Muroi K, Motomura S,
Murakami M, Takeyama H, Ohsaka A and Urabe A: Interstitial
pneumonia in patients receiving granulocyte colony-stimulating
factor during chemotherapy: Survey in Japan 1991–96. Br J Cancer.
76:1661–1666. 1997. View Article : Google Scholar : PubMed/NCBI
|
